Compare IDEXX Laboratories, Inc. (IDXX) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs MobilEye Global Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while MobilEye Global Inc trades at $7.1 (market cap $6.00B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.7× MobilEye Global Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 7,007,849). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and MobilEye Global Inc for 15 Days on average.
| IDXX | MBLY | |
|---|---|---|
Market Cap | $40.43B | $6.00B |
Volume | 692,164 | 7,007,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $15.42 |
52-Week Low | $504.70 | $6.56 |
Typical Hold Time | 46 Days | 15 Days |
Enterprise Value | $41.32B | $4.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Mobileye Global (MBLY) trades at $7.06, down 1.26% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $1.9B in 2025 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus leans bullish with a $10.83 price target, while institutional activity shows mixed positioning amid autonomous driving sector volatility.
MBLY presents a high-risk opportunity with substantial upside potential if profitability improves, but current negative margins and bearish technicals suggest caution. The autonomous driving market position remains strong, though execution risks and competitive pressures could limit near-term gains despite Wall Street's optimistic price targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
